Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cipla's gross profit for the
three
months ended in Jun. 2026 was $464 Mil. Cipla's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $1,960 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Cipla's gross profit for the
three
months ended in Jun. 2026 was $464 Mil. Cipla's Revenue for the
three
months ended in Jun. 2026 was $745 Mil. Therefore, Cipla's Gross Margin % for the quarter that ended in Jun. 2026 was 62.31%.
Cipla had a gross margin of 62.31% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Cipla was 64.06%. The lowest was 57.32%. And the median was 60.15%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cipla had a gross margin of 62.31% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Cipla Gross Profit Related Terms
Cipla Gross Profit Historical Data
* Premium members only.
The historical data trend for Cipla's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's Gross Profit distribution charts can be found below:
* The bar in red indicates where Cipla's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,960 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Cipla's Gross Margin % for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cipla (LUX:CIPLA) has a Gross Profit of $1,960 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Cipla and its competitors.
Is Cipla's Gross Profit too high?
Cipla's current Gross Profit is $1,960 Mil. Overall, Cipla has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's Gross Profit compare to ZTS?
Cipla's Gross Profit of $1,960 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Cipla and its competitors. Cipla's current Gross Profit is $1,960 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current Gross Profit of $1,960 Mil. The stock's GF Value™ is $19.34, compared to a current price of $18.10 — trading 6.4% below its estimated fair value. The current Gross Profit is $1,960 Mil. Cipla's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current Gross Profit is $1,960 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipla (LUX:CIPLA) Overvalued in 2026?
Based on GuruFocus' analysis, Cipla stock appears to be undervalued.
The current stock price of $18.10 is trading 6.4% below its estimated GF Value™ of $19.34.
Key valuation signals for LUX:CIPLA:
Gross Profit: $1,960 Mil
GF Value™: $19.34 vs. price of $18.10 (6.4% below fair value)
No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
82GF Score
Get the complete analysis for LUX:CIPLA
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:CIPLA has been successfully added to your 
